Purdue Pharma L.P. v. Impax Laboratories, Inc.
1:13-cv-03188
Overview
Parties
Defendant
Counter Defendant
Court & Judges
Court
District Court, S.D. New York (nysd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 22 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 8,114,383 Asserted | Asserted Patent | View Official Patent → |
| πΊπΈ United States | US 8,075,872 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2007004822 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,192,722 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,420,056 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,309,060 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2012025163 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2013017107 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2014017007 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2014010583 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2016002258 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2016007438 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 9,629,807 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 10,130,591 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 10,058,548 B2 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8114383
Abuse-proofed dosage form
|
Filed: 2003-11-20
Issued: 2012-02-14
|
Expired (Term Ended)
+325d PTA
Expires: 2024-10-10
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
High PTA (+325 days) / Cellect Scrutiny β Over 325 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
3
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings